. 2023 Mar 24;11(4):723. doi: 10.3390/vaccines11040723

Table 4.

Summary of saliva total Ig response.

	High-Dose (n = 12)	Low-Dose (n = 11)	Placebo (n = 6)	p-Value ¹⁺	p-Value ²⁺	p-Value ³⁺	p-Value ⁴
Day 0 (pre-dose)	0.05 (0.03–0.10)	0.07 (0.04–0.11)	0.08 (0.03–0.13)	0.15	0.93	0.06	0.65
Day 3	0.26 (0.16–0.66)	0.18 (0.08–0.51)	0.32 (0.12–0.72)	0.83	0.99	0.84	0.87
Day 28 (pre-dose)	0.08 (0.03–0.24)	0.07 (0.04–0.17)	0.1 (0.03–0.13)	0.11	0.20	0.36	0.66
Day 31	0.24 (0.13–0.63)	0.21 (0.08–0.50)	0.21 (0.11–0.26)	0.046	0.06	0.99	0.59
Day 56	0.31 (0.09–0.61)	0.31 (0.07–0.48)	0.15 (0.06–0.53)	0.45	0.96	0.45	0.69

High-dose: DelNS1-nCoV-RBD LAIV (1 × 10^7.7 EID₅₀/dose) in 0.2 mL. Low-dose: DelNS1-nCoV-RBD LAIV (1 × 10⁷ EID₅₀/dose) in 0.2 mL. Placebo: inert excipients/ dose in 0.2 mL. p-value ¹: High-dose vs. Placebo. p-value ²: Low-dose vs. Placebo. p-value ³: High-dose vs. Low-dose. + Mann-Whitney U test. p-value ⁴: one-way ANOVA, comparison of three groups. Data were median (IQR).